title: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
abstract: Dopamine agonist administration is the primary therapy for macroprolactinomas, but bromocriptine is the only agent approved in the United States. Its use is limited by a high incidence of side effects, a short duration of action, and a lack of effectiveness in some patients. Cabergoline is a long-acting dopamine agonist specific for the D2 receptor that is more effective and better tolerated than bromocriptine in women with microadenomas or idiopathic hyperprolactinemia. However, experience with cabergoline in the treatment of patients with macroadenomas is limited. We report the first study of chronic administration of cabergoline conducted exclusively in patients with macroprolactinomas. Fifteen patients (8 women, 7 men) ages 18-76 yr were studied in an open-label 48-week dose escalation trial of cabergoline administered once per week. Eleven patients had received prior therapy with other dopamine agonists. Mean prolactin (PRL) levels decreased by 93.6%, and normal levels were attained in 73% of patients at doses of 0.5-3.0 mg per week. Three of five patients who had failed to normalize PRL on prior dopamine agonists achieved normal levels. Gonadal function was restored in all hypogonadal men and in 75% of premenopausal women with amenorrhea. Tumor size decreased in 11 of the 15 patients. Side effects were minimal. Of the 5 patients who had experienced side effects in prior dopamine agonists, 4 had none on cabergoline, and the fifth had milder symptoms. During two further years of follow up, the improvement in PRL levels, gonadal function, and tumor size has persisted during cabergoline administration, and three patients have experienced a further decline in PRL and/or tumor size. This study demonstrates the effectiveness and minimal side effects of once-weekly cabergoline for treatment of macroprolactinomas.
authors.affiliation: Neuroendocrine Unit, Massachusetts General Hospital, Boston 02114, USA.
authors.forename: B M
authors.initials: BM
authors.lastname: Biller
authors.forename: M E
authors.initials: ME
authors.lastname: Molitch
authors.forename: M L
authors.initials: ML
authors.lastname: Vance
authors.forename: K B
authors.initials: KB
authors.lastname: Cannistraro
authors.forename: K R
authors.initials: KR
authors.lastname: Davis
authors.forename: J A
authors.initials: JA
authors.lastname: Simons
authors.forename: J R
authors.initials: JR
authors.lastname: Schoenfelder
authors.forename: A
authors.initials: A
authors.lastname: Klibanski
mesh_terms: D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006066:Gonads / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000503:physiopathology; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D014794:Visual Fields / Q000187:drug effects
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline